Urovant Sciences, Inc
5281 California Ave, Suite #100
Irvine
California
92617
United States
Tel: +1 949 226 6029
Website: https://urovant.com/
Email: info@urovant.com
About Urovant Sciences, Inc
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology. At Urovant Sciences, we aim to advance urological patient care through execution of our core values:
Integrity and Compassion
Our commitment to improving patients’ lives begins with personal integrity and how we treat each other.
Bold Innovation
We deliver bold innovation through diversity of thought, openness to new ideas and adaptation to change.
Achievement Through Collaboration
We achieve excellence by uniquely optimizing our collective individual strengths and expertise.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Every team member has the ability to make an impact to our success.
We are ambitious in our approach to improve outcomes for the patients and healthcare providers we serve. To challenge team members and grow careers, we reward innovation, teamwork, and a winning mindset that produces results.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
111 articles with Urovant Sciences, Inc
-
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
3/19/2019
Vibegron met both co-primary endpoints and all seven key secondary endpoints
-
The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.
-
Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
3/18/2019
Urovant Sciences announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivotal phase 3 study on Tuesday, March 19, 2019 at 8:30 a.m. ET.
-
Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
2/22/2019
Urovant Sciences announced it has entered into a debt financing agreement with Hercules Capital, Inc. for up to $100 million.
-
Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
2/13/2019
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018.
-
Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
2/6/2019
Urovant Sciences Ltd. announced it will report 2018 third fiscal quarter financial results after the close of U.S. financial markets on Wednesday, February 13, 2019.
-
Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
1/15/2019
The event will feature presentations by clinical experts in the field of urology, Dr. Roger R. Dmochowski, Vanderbilt University, and Dr. Steven Kaplan, Icahn School of Medicine at Mount Sinai.
-
Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
1/3/2019
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018.
-
Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
12/19/2018
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced chief executive officer Keith A. Katkin is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 a.m. PT in San Francisco.
-
Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
11/19/2018
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to participate in the Piper Jaffray Healthcare Conference on Tuesday, November 27
-
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
-
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
11/12/2018
Urovant Sciences Ltd. today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.
-
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
-
Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
11/8/2018
More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target
-
Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology
11/1/2018
The study demonstrated once-daily vibegron was well-tolerated and improved OAB symptoms
-
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
-
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
-
Kyorin Receives Approval from Japan's Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
9/24/2018
Kyorin secures first commercial approval for vibegron
-
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
-
Urovant Sciences Licenses Novel Gene Therapy for Overactive Bladder
8/28/2018
There are no currently available FDA-approved gene therapy treatments for overactive bladder